{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:03:46Z","timestamp":1793822626634,"version":"4.6.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lewy-body pathology with aggregation of abnormal conformations of the protein alpha-synuclein (\u03b1-Syn) represent the histopathological hallmarks of Parkinson\u2019s disease (PD). Genetic prototypes such as PD due to mutations in the <jats:italic>alpha-synuclein<\/jats:italic> gene (<jats:italic>SNCA<\/jats:italic>) offer the opportunity to evaluate \u03b1-Syn-related profiles in patient-derived biomaterial. We identified a family with a <jats:italic>SNCA<\/jats:italic> triplication and assessed the index patient for CSF \u03b1-Syn seeding capacity and levels of total \u03b1-Syn along with other neurodegenerative CSF markers (A\u03b2<jats:sub>1-42<\/jats:sub>, total-Tau, phospho-Tau, NFL). As no published CSF data in patients with <jats:italic>SNCA<\/jats:italic> triplication are available, we descriptively compared his CSF profiles to those of sporadic PD patients and PD patients with <jats:italic>GBA<\/jats:italic> mutations as these are also specifically associated with prominent \u03b1-Syn pathology. Additionally, skin biopsies with staining for phospho-\u03b1-Syn were done. To assess cerebral glucose metabolism and brain atrophy combined positron emission tomography and magnetic resonance imaging ([<jats:sup>18<\/jats:sup>F]FDG-PET\/MRI) was performed. Age at onset was 24 years and motor impairment was accompanied by prominent non-motor symptoms with early development of dementia, depression, REM sleep behavior disorder, hyposmia, and dysautonomia. Correspondingly, PET-MRI showed hypometabolism and atrophy in frontal, temporoparietal and occipital regions. CSF levels of total \u03b1-Syn were threefold higher and RT-QuIC showed remarkable \u03b1-Syn seeding activity in all kinetic categories in the SNCA<jats:sub>Triplication<\/jats:sub> patient compared to patients with <jats:italic>GBA<\/jats:italic> mutations. Our results are consistent with findings that not only mutant forms but also overexpression of the wild-type \u03b1-Syn protein lead to PD and PD dementia and show a striking CSF \u03b1-Syn seeding profile, thus substantiating the role of RT-QuIC as a specific in vivo biomarker of \u03b1-Syn brain pathology.<\/jats:p>","DOI":"10.1038\/s41531-022-00379-8","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T12:07:47Z","timestamp":1663243667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Linking the phenotype of SNCA Triplication with PET-MRI imaging pattern and alpha-synuclein CSF seeding"],"prefix":"10.1038","volume":"8","author":[{"given":"Isabel","family":"Wurster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0302-3027","authenticated-orcid":false,"given":"Corinne","family":"Quadalti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kathrin","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Deuschle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Waniek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingolf","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"la Fougere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2883-0009","authenticated-orcid":false,"given":"Kathrin","family":"Doppler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1069-1146","authenticated-orcid":false,"given":"Thomas","family":"Gasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3205-4631","authenticated-orcid":false,"given":"Benjamin","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9444-9524","authenticated-orcid":false,"given":"Piero","family":"Parchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7515-8596","authenticated-orcid":false,"given":"Kathrin","family":"Brockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"key":"379_CR1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. Alpha-synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"379_CR2","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos, M. H. et al. Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science 276, 2045\u20132047 (1997).","journal-title":"Science"},{"key":"379_CR3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/ng0298-106","volume":"18","author":"R Kruger","year":"1998","unstructured":"Kruger, R. et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson\u2019s disease. Nat. Genet. 18, 106\u2013108 (1998).","journal-title":"Nat. Genet."},{"key":"379_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1090278","volume":"302","author":"AB Singleton","year":"2003","unstructured":"Singleton, A. B. et al. alpha-Synuclein locus triplication causes Parkinson\u2019s disease. Science 302, 841 (2003).","journal-title":"Science"},{"key":"379_CR5","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","volume":"364","author":"MC Chartier-Harlin","year":"2004","unstructured":"Chartier-Harlin, M. C. et al. Alpha-synuclein locus duplication as a cause of familial Parkinson\u2019s disease. Lancet 364, 1167\u20131169 (2004).","journal-title":"Lancet"},{"key":"379_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/ana.67","volume":"49","author":"PJ Spira","year":"2001","unstructured":"Spira, P. J., Sharpe, D. M., Halliday, G., Cavanagh, J. & Nicholson, G. A. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann. Neurol. 49, 313\u2013319 (2001).","journal-title":"Ann. Neurol."},{"key":"379_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1212\/01.wnl.0000299387.59159.db","volume":"70","author":"T Obi","year":"2008","unstructured":"Obi, T. et al. Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia. Neurology 70, 238\u2013241 (2008).","journal-title":"Neurology"},{"key":"379_CR8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ana.10846","volume":"55","author":"M Farrer","year":"2004","unstructured":"Farrer, M. et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 55, 174\u2013179 (2004).","journal-title":"Ann. Neurol."},{"key":"379_CR9","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul, G. et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann. Clin. Transl. Neurol. 3, 812\u2013818 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"379_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","volume":"74","author":"M Shahnawaz","year":"2017","unstructured":"Shahnawaz, M. et al. Development of a biochemical diagnosis of Parkinson disease by detection of alpha-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol. 74, 163\u2013172 (2017).","journal-title":"JAMA Neurol."},{"key":"379_CR11","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/mds.27646","volume":"34","author":"UJ Kang","year":"2019","unstructured":"Kang, U. J. et al. Comparative study of cerebrospinal fluid alpha-synuclein seeding aggregation assays for diagnosis of Parkinson\u2019s disease. Mov. Disord. 34, 536\u2013544 (2019).","journal-title":"Mov. Disord."},{"key":"379_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-021-01276-6","volume":"9","author":"K Brockmann","year":"2021","unstructured":"Brockmann, K. et al. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson\u2019s disease and dementia with Lewy bodies. Acta Neuropathol. Commun. 9, 175 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"379_CR13","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/brain\/awp044","volume":"132","author":"J Neumann","year":"2009","unstructured":"Neumann, J. et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson\u2019s disease. Brain 132, 1783\u20131794 (2009).","journal-title":"Brain"},{"key":"379_CR14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3389\/fneur.2018.01021","volume":"9","author":"A Book","year":"2018","unstructured":"Book, A. et al. A meta-analysis of alpha-synuclein multiplication in familial parkinsonism. Front. Neurol. 9, 1021 (2018).","journal-title":"Front. Neurol."},{"key":"379_CR15","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1002\/mds.23313","volume":"25","author":"T Sekine","year":"2010","unstructured":"Sekine, T. et al. Clinical course of the first Asian family with Parkinsonism related to SNCA triplication. Mov. Disord. 25, 2871\u20132875 (2010).","journal-title":"Mov. Disord."},{"key":"379_CR16","first-page":"546462","volume":"2015","author":"R Ferese","year":"2015","unstructured":"Ferese, R. et al. Four copies of SNCA responsible for autosomal dominant Parkinson\u2019s disease in two Italian siblings. Parkinsons Dis. 2015, 546462 (2015).","journal-title":"Parkinsons Dis."},{"key":"379_CR17","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.parkreldis.2015.06.005","volume":"21","author":"S Olgiati","year":"2015","unstructured":"Olgiati, S. et al. Early-onset parkinsonism caused by alpha-synuclein gene triplication: clinical and genetic findings in a novel family. Parkinsonism Relat. Disord. 21, 981\u2013986 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"379_CR18","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1212\/01.WNL.0000127517.33208.F4","volume":"62","author":"DW Miller","year":"2004","unstructured":"Miller, D. W. et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62, 1835\u20131838 (2004).","journal-title":"Neurology"},{"key":"379_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41531-018-0054-4","volume":"4","author":"F Zafar","year":"2018","unstructured":"Zafar, F. et al. Genetic fine-mapping of the Iowan SNCA gene triplication in a patient with Parkinson\u2019s disease. NPJ Parkinsons Dis. 4, 18 (2018).","journal-title":"NPJ Parkinsons Dis."},{"key":"379_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1453","volume":"2","author":"MJ Devine","year":"2011","unstructured":"Devine, M. J. et al. Parkinson\u2019s disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nat. Commun. 2, 440 (2011).","journal-title":"Nat. Commun."},{"key":"379_CR21","doi-asserted-by":"publisher","first-page":"e26159","DOI":"10.1371\/journal.pone.0026159","volume":"6","author":"B Byers","year":"2011","unstructured":"Byers, B. et al. SNCA triplication Parkinson\u2019s patient\u2019s iPSC-derived DA neurons accumulate alpha-synuclein and are susceptible to oxidative stress. PLoS ONE 6, e26159 (2011).","journal-title":"PLoS ONE"},{"key":"379_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09362-3","volume":"7","author":"W Haenseler","year":"2017","unstructured":"Haenseler, W. et al. Excess alpha-synuclein compromises phagocytosis in iPSC-derived macrophages. Sci. Rep. 7, 9003 (2017).","journal-title":"Sci. Rep."},{"key":"379_CR23","doi-asserted-by":"publisher","first-page":"fcab223","DOI":"10.1093\/braincomms\/fcab223","volume":"3","author":"NV Mohamed","year":"2021","unstructured":"Mohamed, N. V. et al. Midbrain organoids with an SNCA gene triplication model key features of synucleinopathy. Brain Commun. 3, fcab223 (2021).","journal-title":"Brain Commun."},{"key":"379_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ane.12247","volume":"130","author":"N Malek","year":"2014","unstructured":"Malek, N. et al. Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson\u2019s disease - a systematic review. Acta Neurol. Scand. 130, 59\u201372 (2014).","journal-title":"Acta Neurol. Scand."},{"key":"379_CR25","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/mds.27806","volume":"34","author":"B Mollenhauer","year":"2019","unstructured":"Mollenhauer, B. et al. Longitudinal analyses of cerebrospinal fluid alpha-Synuclein in prodromal and early Parkinson\u2019s disease. Mov. Disord. 34, 1354\u20131364 (2019).","journal-title":"Mov. Disord."},{"key":"379_CR26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/mds.27884","volume":"35","author":"S Lerche","year":"2020","unstructured":"Lerche, S. et al. Parkinson\u2019s disease: glucocerebrosidase 1 mutation severity is associated with CSF alpha-synuclein profiles. Mov. Disord. 35, 495\u2013499 (2020).","journal-title":"Mov. Disord."},{"key":"379_CR27","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/mds.28472","volume":"36","author":"S Lerche","year":"2021","unstructured":"Lerche, S. et al. The mutation matters: CSF profiles of GCase, sphingolipids, alpha-synuclein in PDGBA. Mov. Disord. 36, 1216\u20131228 (2021).","journal-title":"Mov. Disord."},{"key":"379_CR28","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/mds.27731","volume":"34","author":"S Lerche","year":"2019","unstructured":"Lerche, S. et al. Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile. Mov. Disord. 34, 1069\u20131073 (2019).","journal-title":"Mov. Disord."},{"key":"379_CR29","doi-asserted-by":"publisher","first-page":"e348","DOI":"10.1212\/NXG.0000000000000348","volume":"5","author":"H Iwaki","year":"2019","unstructured":"Iwaki, H. et al. Genetic risk of Parkinson disease and progression: an analysis of 13 longitudinal cohorts. Neurol. Genet. 5, e348 (2019).","journal-title":"Neurol. Genet."},{"key":"379_CR30","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/mds.10459","volume":"18","author":"I Litvan","year":"2003","unstructured":"Litvan, I. et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord. 18, 467\u2013486 (2003).","journal-title":"Mov. Disord."},{"key":"379_CR31","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement Disorder Society-Sponsored Revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129\u20132170 (2008).","journal-title":"Mov. Disord."},{"key":"379_CR32","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz, C. G. et al. Movement disorder society task force report on the Hoehn and Yahr staging scale: Status and recommendations. Mov. Disord. 19, 1020\u20131028 (2004).","journal-title":"Mov. Disord."},{"key":"379_CR33","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1212\/WNL.0b013e3181c34b47","volume":"73","author":"S Hoops","year":"2009","unstructured":"Hoops, S. et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73, 1738\u20131745 (2009).","journal-title":"Neurology"},{"key":"379_CR34","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/jgs.14779","volume":"65","author":"D Bergeron","year":"2017","unstructured":"Bergeron, D. et al. Multicenter validation of an MMSE-MoCA conversion table. J. Am. Geriatr. Soc. 65, 1067\u20131072 (2017).","journal-title":"J. Am. Geriatr. Soc."},{"key":"379_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi, M. et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol. 140, 49\u201362 (2020).","journal-title":"Acta Neuropathol."},{"key":"379_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-018-0508-2","volume":"6","author":"BR Groveman","year":"2018","unstructured":"Groveman, B. R. et al. Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC. Acta Neuropathol. Commun. 6, 7 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"379_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00401-014-1284-0","volume":"128","author":"K Doppler","year":"2014","unstructured":"Doppler, K. et al. Cutaneous neuropathy in Parkinson\u2019s disease: a window into brain pathology. Acta Neuropathol. 128, 99\u2013109 (2014).","journal-title":"Acta Neuropathol."},{"key":"379_CR38","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3389\/fneur.2018.01094","volume":"9","author":"K Doppler","year":"2018","unstructured":"Doppler, K. et al. Dermal phospho-alpha-synuclein deposition in patients with Parkinson\u2019s disease and mutation of the glucocerebrosidase gene. Front. Neurol. 9, 1094 (2018).","journal-title":"Front. Neurol."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00379-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00379-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00379-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T12:51:21Z","timestamp":1663246281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00379-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["379"],"URL":"https:\/\/doi.org\/10.1038\/s41531-022-00379-8","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"assertion":[{"value":"29 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing non-financial interests but the following competing financial interests: K.W. and I.L. are employed by Roboscreen GmbH, which manufactures the ELISA kit for measurements of total human \u03b1-synuclein used in the present study; B.B. is Co-Founder, Shareholder and CTO of AIRamed GmbH.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethical Committee of the University of Tuebingen (628-2014BO1). All participants gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"117"}}